NASDAQ:SVA - Sinovac Biotech Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$7.55 -0.31 (-3.94 %)
(As of 09/25/2018 01:39 AM ET)
Previous Close$7.86
Today's Range$7.55 - $7.91
52-Week Range$6.06 - $8.75
Volume18,700 shs
Average Volume47,290 shs
Market Capitalization$448.17 million
P/E RatioN/A
Dividend YieldN/A
Beta0.35
Sinovac Biotech logoSinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B, enterovirus 71 (EV71), seasonal influenza, H5N1 and H1N1 pandemic influenza, and mumps, as well as hand, foot, and mouth diseases. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also completed phase III clinical trials for varicella and pneumococcal polysaccharide vaccines. In addition, it has completed Phase I/II clinical trials for Sabin inactivated polio; and focuses on commencing clinical trials for pneumococcal conjugate vaccine, rubella vaccine, and quadrivalent influenza vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; and Tianjin CanSino Biotechnology Inc. to develop a pneumococcal conjugate vaccine. Sinovac Biotech Ltd. was founded in 1999 and is headquartered in Beijing, the People's Republic of China.

Receive SVA News and Ratings via Email

Sign-up to receive the latest news and ratings for SVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SVA
CUSIPN/A
Phone86-10-5693-1800

Debt

Debt-to-Equity Ratio0.08
Current Ratio2.20
Quick Ratio1.99

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$174.35 million
Price / Sales2.47
Cash Flow$0.4906 per share
Price / Cash15.39
Book Value$3.11 per share
Price / Book2.43

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees644
Outstanding Shares57,020,000
Market Cap$448.17 million

Sinovac Biotech (NASDAQ:SVA) Frequently Asked Questions

What is Sinovac Biotech's stock symbol?

Sinovac Biotech trades on the NASDAQ under the ticker symbol "SVA."

How were Sinovac Biotech's earnings last quarter?

Sinovac Biotech Ltd. (NASDAQ:SVA) posted its quarterly earnings data on Tuesday, August, 23rd. The biopharmaceutical company reported ($0.15) earnings per share for the quarter. The biopharmaceutical company earned $1.38 billion during the quarter, compared to analysts' expectations of $18.49 billion. During the same period in the previous year, the business posted $0.02 earnings per share. View Sinovac Biotech's Earnings History.

Who are some of Sinovac Biotech's key competitors?

Who are Sinovac Biotech's key executives?

Sinovac Biotech's management team includes the folowing people:
  • Dr. Weidong Yin, Chairman, Pres, CEO & Sec. (Age 53)
  • Ms. Nan Wang, CFO & VP of Bus. Devel. (Age 52)
  • Ms. Xiaomei Yin, VP of Sales & Marketing (Age 53)
  • Mr. Gao Qiang, VP of R&D (Age 41)
  • Ms. Li Jing, VP of Quality & Production (Age 43)

Who are Sinovac Biotech's major shareholders?

Sinovac Biotech's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (4.44%), Sapphire Star Partners LP (0.17%), California Public Employees Retirement System (0.12%), Yorktown Management & Research Co Inc (0.11%), Eqis Capital Management Inc. (0.07%) and Spark Investment Management LLC (0.07%). Company insiders that own Sinovac Biotech stock include James Todd Parsons and Scott Langille. View Institutional Ownership Trends for Sinovac Biotech.

Which institutional investors are selling Sinovac Biotech stock?

SVA stock was sold by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc., Renaissance Technologies LLC, Spark Investment Management LLC and California Public Employees Retirement System. View Insider Buying and Selling for Sinovac Biotech.

Which institutional investors are buying Sinovac Biotech stock?

SVA stock was purchased by a variety of institutional investors in the last quarter, including Sapphire Star Partners LP, Yorktown Management & Research Co Inc and Navellier & Associates Inc. View Insider Buying and Selling for Sinovac Biotech.

How do I buy shares of Sinovac Biotech?

Shares of SVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sinovac Biotech's stock price today?

One share of SVA stock can currently be purchased for approximately $7.55.

How big of a company is Sinovac Biotech?

Sinovac Biotech has a market capitalization of $448.17 million and generates $174.35 million in revenue each year. Sinovac Biotech employs 644 workers across the globe.

What is Sinovac Biotech's official website?

The official website for Sinovac Biotech is http://www.sinovac.com.

How can I contact Sinovac Biotech?

Sinovac Biotech's mailing address is 39 SHANGDI XI ROAD HAIDIAN DISTRICT, BEIJING F4, 102200. The biopharmaceutical company can be reached via phone at 86-10-5693-1800 or via email at [email protected]


MarketBeat Community Rating for Sinovac Biotech (NASDAQ SVA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  177 (Vote Outperform)
Underperform Votes:  157 (Vote Underperform)
Total Votes:  334
MarketBeat's community ratings are surveys of what our community members think about Sinovac Biotech and other stocks. Vote "Outperform" if you believe SVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel